SynthesisMovement disorders clinical practice2026
Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Synthesis in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment.
objectiveWe performed a systematic review and meta-analysis to assess its clinical efficacy and safety.
methodsElectronic searches of MEDLINE, EMBASE, and Cochrane Library were performed on November 2025 to identify clinical trials of defined homogenous cell populations in PD. Eligible studies required validated outcome reporting and extractable data. Continuous measures were synthesized as mean differences (MD) under fixed- or random-effects models depending on heterogeneity. Risk of bias was appraised using Cochrane methodology.
resultsTwenty studies including 374 patients met inclusion criteria, of which 14 contributed to pooled analyses. In the OFF state, homogenous cell transplantation demonstrated consistent, statistically significant improvements in total UPDRS at 3 months [Mean Difference (MD) 22.04, 95% CI 17.40-26.68], 6 months [27.09, 15.47-38.70], 12 months [29.13, 18.04-40.21], and 24 months [21.01, 3.97-38.06]; benefits attenuated beyond 36 months [9.93, -2.16-22.02]. Motor UPDRS III showed robust gains across all intervals, particularly in the OFF state at 3 months [14.34, 11.22-17.45] and 12 months [13.59, 10.22-16.97]. ON-state outcomes were less consistent, with modest improvements limited to 6 and 24 months. Subgroup analyses indicated beneficial responses with dopaminergic progenitor and retinal pigment epithelial grafts. Reported adverse events were generally mild, transient, and perioperative in nature.
conclusionsIn these open label studies of PD patients, homogenous cell transplantation is associated with meaningful and durable motor improvements, particularly in the OFF state, and demonstrates a favorable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.